HOOK - Catalyst on 23/05/2024HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Disclaimer: This content is for informational purposes only and is not intended as financial advice.
Upcoming Catalyst - Date: 23/05/2024
Investment Overview (Dated 27/04/2024):
Relative Volume: 3.90
Shares Float: 70.4 million
Significant Event - Date: 24/05/2024
Event: Hookipa to receive $10M from Roche following FDA clearance for a cancer trial.
Key Technical Levels:
Resistance Levels: Watch for resistance at $1.00, $1.35, and $1.90. A break above these levels could indicate a potential upward movement. Consider taking partial profits at these thresholds to realize gains.
Trading Strategy:
Take Profit (TP): Set a profit target at approximately $2.90 to maximize returns.
Stop Loss (SL): Establish a stop loss strategy below $0.70 to minimize potential losses.
Chart Analysis:
Please refer to the accompanying chart for a detailed visual analysis of price actions and trend lines.
Trading Caution:
Trade with careful consideration of market conditions and personal risk tolerance. It is advised to conduct thorough research or consult with a financial advisor before making any investment decisions.
HOOK trade ideas
HOOKIPA Pharma (USA: $HOOK) Look For An Imminent Eruption! 🌋HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
HOOKIPA Pharma Inc 🧙HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
HOOK General/Rough Short Position Analysis Overall:
* Negative EPS
* June 7th conference @ASCO will most likely lead to a double-top.
* The "surge" is starting to end, if not has already ended. Share price should return to anywhere between $8-11, possibly even lower.
* Medical breakthroughs, as a whole, when it comes to cancers, which this company focuses on, are slow, unlikely, and uncommon. And I suspect, the share price will not be Mooning, anytime soon.
Hookia Pharma Soars on early stage FDA approval +++++++ HOT STOCK FOR FRIDAY +++++++++
Shares of Hookipa Pharma Inc. (HOOK) surged in after-hours trading Thursday after the company said the FDA approved an early stage trial of its treatment for human papilloma virus (HPV)-positive cancers.
The stock rose $2.46, or 37% to $9.14 in after-hours action.
The company said in a statement that it intends to start the phase 1/2 clinical trial of its TheraT immunotherapy in the second half of 2019 with preliminary safety and efficacy data expected in late 2020 or early 2021.
Human papilloma virus is estimated to cause about 5% of the worldwide burden of cancer including approximately 99% of cervical cancers, 25% to 60% of head and neck cancers, 70% of vaginal cancers and 88% of anal cancers, the company said.
Source The Street